Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity
Cochrane Database of Systematic Reviews · 2025
DOI: 10.1002/14651858.cd015900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Database of Systematic Reviews, 2025. Verfasst von Huai Leng Pisaniello und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic, Arthritis, Rheumatoid. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To investigate the benefits and harms of dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in adults with rheumatoid arthritis or psoriatic arthritis, who have been in sustained remission or low disease activity. This is a common review protocol, outlining the approach for two separate Cochrane reviews for people with rheumatoid arthritis or psoriatic arthritis. Dose reduction or discontinuation of csDMARDs in adults with rheumatoid arthritis, who have been in sustained remission or low disease activity Dose reduction or discontinuation of csDMARDs in adults with psoriatic arthritis, who have been in sustained remission or low disease activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
- Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia.
ORCID-Profile: Huai Leng Pisaniello
Zitieren
APA
Pisaniello, H. L., Whittle, S. L., Johnston, R. V., Glennon, V., Grobler, L., Cyril, S., Arno, A. D., & Buchbinder, R. (2025). Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd015900
Vancouver
Pisaniello HL, Whittle SL, Johnston RV, Glennon V, Grobler L, Cyril S, et al. Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity. Cochrane Database of Systematic Reviews. 2025. doi:10.1002/14651858.cd015900
BibTeX
@article{Pisaniello2025,
author = {Pisaniello, Huai Leng and Whittle, Samuel L and Johnston, Renea V and Glennon, Vanessa and Grobler, Liesl and Cyril, Sheila and Arno, Anneliese D and Buchbinder, Rachelle},
title = {Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity},
journal = {Cochrane Database of Systematic Reviews},
year = {2025},
doi = {10.1002/14651858.cd015900}
}
EUVIMED